{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:06:08Z","timestamp":1789387568903,"version":"build-2803163510"},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:sec id=\"ab-soi230029-4\"><jats:title>Importance<\/jats:title><jats:p>The increasing use of neoadjuvant systemic therapy (NST) has led to substantial pathological complete response rates in patients with initially node-positive, early breast cancer, thereby questioning the need for axillary lymph node dissection (ALND). Targeted axillary dissection (TAD) is feasible for axillary staging; however, data on oncological safety are scarce.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi230029-5\"><jats:title>Objective<\/jats:title><jats:p>To assess 3-year clinical outcomes in patients with node-positive breast cancer who underwent TAD alone or TAD with ALND.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi230029-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The SenTa study is a prospective registry study and was conducted between January 2017 and October 2018. The registry includes 50 study centers in Germany. Patients with clinically node-positive breast cancer underwent clipping of the most suspicious lymph node (LN) before NST. After NST, the marked LNs and sentinel LNs were excised (TAD) followed by ALND according to the clinician\u2019s choice. Patients who did not undergo TAD were excluded. Data analysis was performed in April 2022 after 43 months of follow-up.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi230029-7\"><jats:title>Exposure<\/jats:title><jats:p>TAD alone vs TAD with ALND.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi230029-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Three-year clinical outcomes were evaluated.<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi230029-9\"><jats:title>Results<\/jats:title><jats:p>Of 199 female patients, the median (IQR) age was 52 (45-60) years. A total of 182 patients (91.5%) had 1 to 3 suspicious LNs; 119 received TAD alone and 80 received TAD with ALND. Unadjusted invasive disease-free survival was 82.4% (95% CI, 71.5-89.4) in the TAD with ALND group and 91.2% (95% CI, 84.2-95.1) in the TAD alone group (<jats:italic>P<\/jats:italic>\u2009=\u2009.04); axillary recurrence rates were 1.4% (95% CI, 0-54.8) and 1.8% (95% CI, 0-36.4), respectively (<jats:italic>P<\/jats:italic>\u2009=\u2009.56). Adjusted multivariate Cox regression indicated that TAD alone was not associated with an increased risk of recurrence (hazard ratio [HR], 0.83; 95% CI, 0.34-2.05; <jats:italic>P<\/jats:italic>\u2009=\u2009.69) or death (HR, 1.07; 95% CI, 0.31-3.70; <jats:italic>P<\/jats:italic>\u2009=\u2009.91). Similar results were obtained for 152 patients with clinically node-negative breast cancer after NST (invasive disease-free survival: HR, 1.26; 95% CI, 0.27-5.87; <jats:italic>P<\/jats:italic>\u2009=\u2009.77; overall survival: HR, 0.81; 95% CI, 0.15-3.83; <jats:italic>P<\/jats:italic>\u2009=\u2009.74).<\/jats:p><\/jats:sec><jats:sec id=\"ab-soi230029-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These results suggest that TAD alone in patients with mostly good clinical response to NST and at least 3 TAD LNs may confer survival outcomes and recurrence rates similar to TAD with ALND.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamasurg.2023.1772","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T15:03:25Z","timestamp":1686150205000},"page":"807","source":"Crossref","is-referenced-by-count":89,"title":["Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer"],"prefix":"10.1001","volume":"158","author":[{"given":"Sherko","family":"Kuemmel","sequence":"first","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"},{"name":"Department of Gynecology With Breast Center Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Heil","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bruzas","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Breit","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Schindowski","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakima","family":"Harrach","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouafaa","family":"Chiari","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hellerhoff","sequence":"additional","affiliation":[{"name":"Breast Unit, Rotkreuzklinikum M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bensmann","sequence":"additional","affiliation":[{"name":"Breast Unit, Rotkreuzklinikum M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Hanf","sequence":"additional","affiliation":[{"name":"Breast Unit Klinikum F\u00fcrth, Frauenklinik Nathanstift, F\u00fcrth, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Thomas","family":"Gra\u00dfhoff","sequence":"additional","affiliation":[{"name":"Breast Unit, Harzklinikum Dorothea Christiane Erxleben, Wernigerode, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Deuschle","sequence":"additional","affiliation":[{"name":"Breast Unit, Marienhaus Klinikum Hetzelstift Neustadt\/Weinstra\u00dfe, Neustadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Belke","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Robert-Koch-Krankenhaus Apolda, Apolda, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Polata","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin\/Onkologisches Zentrum, Evangelisches Waldkrankenhaus Spandau, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Paepke","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Frauenheilkunde, Klinikum rechts der Isar, TU M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Warm","sequence":"additional","affiliation":[{"name":"Brustzentrum Holweide, Kliniken der Stadt K\u00f6ln, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Meiler","sequence":"additional","affiliation":[{"name":"MVZ Onkologie, Klinik Dr. Hancken, Stade, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schindlbeck","sequence":"additional","affiliation":[{"name":"Frauenklinik S\u00fcdostbayern, Klinikum Traunstein, Traunstein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencke","family":"Ruhwedel","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Frauenheilkunde und Geburtshilfe, Klinikum G\u00fctersloh, G\u00fctersloh, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Beckmann","sequence":"additional","affiliation":[{"name":"Brustzentrum der Niels-Stensen-Kliniken, Franziskus-Hospital Harderberg, Georgsmarienh\u00fctte, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Groh","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gyn\u00e4kologie, Geburtshilfe und Senologie, Hochwaldkrankenhaus Bad Nauheim, Bad Nauheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dall","sequence":"additional","affiliation":[{"name":"Brustzentrum und Gyn\u00e4kologisches Krebszentrum, St\u00e4dtisches Klinikum L\u00fcneburg, L\u00fcneburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[{"name":"Department of Gynecology With Breast Center Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Traut","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattea","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"},{"name":"Department of Gynecology With Breast Center Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"soi230029r1","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1245\/s10434-018-6531-5","article-title":"Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes.","volume":"25","author":"Murphy","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"soi230029r2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1634\/theoncologist.2018-0228","article-title":"Neoadjuvant management of early breast cancer: a clinical and investigational position statement.","volume":"24","author":"Colomer","year":"2019","journal-title":"Oncologist"},{"issue":"9","key":"soi230029r3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer.","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"soi230029r4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/annonc\/mdw610","article-title":"Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.","volume":"28","author":"Loibl","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"soi230029r5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"soi230029r6","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1097\/SLA.0000000000004572","article-title":"A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients.","volume":"276","author":"Kuemmel","year":"2022","journal-title":"Ann Surg"},{"issue":"7","key":"soi230029r7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","article-title":"Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery.","volume":"152","author":"Tadros","year":"2017","journal-title":"JAMA Surg"},{"issue":"12","key":"soi230029r8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","article-title":"Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy.","volume":"153","author":"Barron","year":"2018","journal-title":"JAMA Surg"},{"issue":"1","key":"soi230029r9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13058-016-0684-6","article-title":"Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.","volume":"18","author":"van la Parra","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"1","key":"soi230029r10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1477-7819-12-67","article-title":"Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients.","volume":"12","author":"Soares","year":"2014","journal-title":"World J Surg Oncol"},{"issue":"3","key":"soi230029r11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-005-9025-7","article-title":"Post-operative arm morbidity and quality of life. results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer.","volume":"95","author":"Fleissig","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"soi230029r12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","article-title":"Axillary nodal management following neoadjuvant chemotherapy: a review.","volume":"3","author":"Pilewskie","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"soi230029r13","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/cancers13071539","article-title":"The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis.","volume":"13","author":"Swarnkar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"soi230029r14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12916-015-0385-5","article-title":"Targeting and limiting surgery for patients with node-positive breast cancer.","volume":"13","author":"Caudle","year":"2015","journal-title":"BMC Med"},{"issue":"2","key":"soi230029r15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"issue":"10","key":"soi230029r16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection.","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"key":"soi230029r17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.suronc.2019.05.019","article-title":"Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: preliminary results.","volume":"30","author":"Flores-Funes","year":"2019","journal-title":"Surg Oncol"},{"issue":"2","key":"soi230029r18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamasurg.2014.1086","article-title":"Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial.","volume":"150","author":"Caudle","year":"2015","journal-title":"JAMA Surg"},{"issue":"3","key":"soi230029r19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000477575","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2017.","volume":"12","author":"Liedtke","year":"2017","journal-title":"Breast Care (Basel)"},{"issue":"6","key":"soi230029r20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology.","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"soi230029r21","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1055\/a-1499-8431","article-title":"AGO recommendations for the surgical therapy of the axilla after neoadjuvant chemotherapy: 2021 update.","volume":"81","author":"Friedrich","year":"2021","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"10","key":"soi230029r22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1055\/a-1904-6231","article-title":"AGO recommendations for the surgical therapy of breast cancer: update 2022.","volume":"82","author":"Banys-Paluchowski","year":"2022","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"7","key":"soi230029r23","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers13071565","article-title":"Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study.","volume":"13","author":"Banys-Paluchowski","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"soi230029r24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejso.2019.08.012","article-title":"Patterns of axillary staging and management in clinically node positive breast cancer patients treated with neoadjuvant systemic therapy: results of a survey amongst breast cancer specialists.","volume":"46","author":"Simons","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"soi230029r25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00129-020-04746-5","article-title":"\u201dTargeted axillary dissection\u201c\u2014standard oder noch experimentell?","volume":"54","author":"Thill","year":"2021","journal-title":"Gynakologe"},{"issue":"3","key":"soi230029r26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000489329","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2018.","volume":"13","author":"Liedtke","year":"2018","journal-title":"Breast Care (Basel)"},{"issue":"4","key":"soi230029r27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000501000","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2019.","volume":"14","author":"Ditsch","year":"2019","journal-title":"Breast Care (Basel)"},{"key":"soi230029r29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.breast.2021.07.015","article-title":"Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: an up-to-date meta-analysis of 3,578 patients.","volume":"59","author":"Cao","year":"2021","journal-title":"Breast"},{"key":"soi230029r30","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.breast.2021.08.018","article-title":"Axillary surgery in node-positive breast cancer.","volume":"62","author":"Maggi","year":"2022","journal-title":"Breast"},{"issue":"4","key":"soi230029r31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up.","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"soi230029r32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2018.10.014","article-title":"Post-neoadjuvant strategies in breast cancer: from risk assessment to treatment escalation.","volume":"72","author":"Pelizzari","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"soi230029r33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"soi230029r34","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"soi230029r35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/bjs.10626","article-title":"Targeted axillary dissection after neoadjuvant therapy in breast cancer.","volume":"105","author":"Ahmed","year":"2018","journal-title":"Br J Surg"},{"issue":"3","key":"soi230029r36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/bjs\/znaa083","article-title":"Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial.","volume":"108","author":"Hartmann","year":"2021","journal-title":"Br J Surg"},{"key":"soi230029r37","doi-asserted-by":"publisher","first-page":"S624","DOI":"10.1016\/j.annonc.2022.07.229","article-title":"194P clinical feasibility and oncological safety of targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective registry study.","volume":"33","author":"Wu","year":"2022","journal-title":"Ann Oncol"},{"issue":"5, suppl","key":"soi230029r38","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-GS4-02","article-title":"Abstract GS4-02: oncological outcomes following omission of axillary lymph node dissection in node positive patients downstaging to node negative with neoadjuvant chemotherapy: the OPBC-04\/EUBREAST-06\/OMA study.","volume":"83","author":"Montagna","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"soi230029r39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-022-06545-z","article-title":"Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.","volume":"193","author":"van Loevezijn","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"soi230029r40","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/bjs.10555","article-title":"Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.","volume":"104","author":"Koolen","year":"2017","journal-title":"Br J Surg"},{"issue":"11","key":"soi230029r41","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/jamasurg.2022.3907","article-title":"Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer.","volume":"157","author":"Simons","year":"2022","journal-title":"JAMA Surg"},{"issue":"6","key":"soi230029r42","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.acra.2018.07.002","article-title":"A review of options for localization of axillary lymph nodes in the treatment of invasive breast cancer.","volume":"26","author":"Woods","year":"2019","journal-title":"Acad Radiol"},{"issue":"16","key":"soi230029r43","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.3390\/cancers13164167","article-title":"Options to determine pathological response of axillary lymph node metastasis after neoadjuvant chemotherapy in advanced breast cancer.","volume":"13","author":"Murthy","year":"2021","journal-title":"Cancers (Basel)"},{"key":"soi230029r44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.breast.2021.03.008","article-title":"The applicability of Magseed for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy.","volume":"57","author":"Reitsamer","year":"2021","journal-title":"Breast"},{"issue":"10","key":"soi230029r45","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.21873\/anticanres.14542","article-title":"De-escalation of axillary surgery in the neoadjuvant chemotherapy (NACT) setting for breast cancer: is it oncologically safe?","volume":"40","author":"Wazir","year":"2020","journal-title":"Anticancer Res"},{"issue":"9","key":"soi230029r46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/djj158","article-title":"Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial.","volume":"98","author":"Mansel","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"soi230029r47","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","article-title":"Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.","volume":"25","author":"Lucci","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"soi230029r48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.21535","article-title":"Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.","volume":"102","author":"Ashikaga","year":"2010","journal-title":"J Surg Oncol"},{"issue":"4, suppl","key":"soi230029r49","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-GS4-03","article-title":"Abstract GS4-03: patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): persistent impact of axillary surgery on arm and breast symptoms in early breast cancer.","volume":"82","author":"Gerber","year":"2022","journal-title":"Cancer Res"},{"issue":"15, suppl","key":"soi230029r50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS600","article-title":"Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC).","volume":"39","author":"Goyal","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"soi230029r51","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","article-title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.","volume":"19","author":"Henke","year":"2018","journal-title":"Trials"},{"key":"soi230029r28","unstructured":"Gradishar? WJ, Anderson? BO, Aft? R, . NCCN Clinical Practice Guidelines in Oncology (NCNN Guidelines): breast cancer. Accessed August 11, 2022. https:\/\/www2.tri-kobe.org\/nccn\/guideline\/archive\/breast2018\/english\/breast_v1.pdf"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2805951\/jamasurgery_kuemmel_2023_oi_230029_1691551376.34051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T15:03:18Z","timestamp":1691593398000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2805951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2023.1772","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}